{"id":519,"date":"2024-01-11T09:18:37","date_gmt":"2024-01-11T01:18:37","guid":{"rendered":"https:\/\/2606175gud45.adwebcloud.com\/?page_id=519"},"modified":"2026-07-30T10:00:59","modified_gmt":"2026-07-30T02:00:59","slug":"home","status":"publish","type":"page","link":"https:\/\/2606175gud45.adwebcloud.com\/en","title":{"rendered":"Home"},"content":{"rendered":"
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

A Leading Biopharmaceutical Company Focused on Critical Care, Anti-Infective, and Respiratory Therapies<\/h2>\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Our Mission<\/h2>\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t

Safeguarding Human Health Through Innovation and Speed<\/h2>\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Our Values<\/h2>\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t

Integrity, Agility, Innovation, Proactivity <\/h2>\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t
\n\t\t\t\t<\/path><\/svg>\t\t\t<\/div>\n\t\t\t
\n\t\t\t\t<\/path><\/svg>\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t\t

ShanZeBIO<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\tSee More<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Shanzebio is a specialized platform company dedicated to the introduction and commercialization of innovative pharmaceutical products from around the world.
Our vision is to become a leader in the biopharmaceutical industry, focusing on critical care, anti-infectives, and respiratory diseases; our mission is to safeguard human health through innovation and speed.
Invested by HSG, we focus on anti-infectives, respiratory diseases, and critical care. Through a commercialization model that combines \u201ccore product operations with the introduction of innovative pipelines\u201d, we are committed to delivering sustainable medical solutions for patients worldwide.
In the future, we will remain rooted in China while leveraging our proven commercialization model and global operational capabilities to bring cutting-edge innovative products to patients worldwide, further advancing human health.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t\t

News<\/h2>\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t
\"\"<\/div><\/a>\n\t\t\t\t
\n\t\t\t\t

\n\t\t\t\n\t\t\t\tAvelox Remains on the 2026 Edition of the National Essential Drug List\t\t\t<\/a>\n\t\t<\/h3>\n\t\t\t\t
\n\t\t\t

On July 9, 2026, the National Health Commission, in collaboration with multiple government departments, released the *National Essential Medicines List (2026 Edition)*, which includes a total of 794 medicines.\u00b9 Among them, Bayful (moxifloxacin hydrochloride tablets\/sodium chloride injection) was successfully retained in the new edition of the National Essential Medicines List due to its outstanding clinical value in the field of anti-infective therapy. A 24-Year Journey in China: From Market Launch to Continued Recognition in the Essential Medicines List Over the past 24 years, Bayfulu\u00ae has served numerous patients with infectious diseases in China. In 2018, moxifloxacin was first included in the *National Essential Medicines List*, and its continued inclusion in the 2026 edition of the list<\/p>\n\t\t<\/div>\n\t\t\t\t\t

\n\t\t\n\t\t\n\t\t\tSee More >\t\t<\/a>\n\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/article>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t
\"\"<\/div><\/a>\n\t\t\t\t
\n\t\t\t\t

\n\t\t\t\n\t\t\t\tJoining Hands to Build a Leading Biopharmaceutical Platform in Anti-infectives, Respiratory Diseases, and Critical Care | ShanZeBIO and SPH Kyuan Trade Enter into Strategic Partnership\t\t\t<\/a>\n\t\t<\/h3>\n\t\t\t\t
\n\t\t\t

Recently, Hangzhou Shanze Biopharmaceutical Co., Ltd. and its parent company, Ascenda Pte. Ltd. (hereinafter referred to as \u201cShanze Biopharmaceutical\u201d), formally signed a strategic cooperation agreement on import distribution with Keyuan Xinhai (Beijing) Medical Supplies Trading Co., Ltd. (hereinafter referred to as \u201cShangyao Keyuan Trading\u201d). The two parties announced that they will engage in in-depth cooperation centered on Shanze Bio\u2019s flagship product\u2014Moxifloxacin Hydrochloride and Sodium Chloride Injection (brand name: Baifulu\u00ae). Bai Fu Le\u00ae is a fluoroquinolone antibiotic that was first approved for marketing in Europe and the United States in 1999 and entered the Chinese market in 2002. To date, it has served over<\/p>\n\t\t<\/div>\n\t\t\t\t\t

\n\t\t\n\t\t\n\t\t\tSee More >\t\t<\/a>\n\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/article>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t
\"\"<\/div><\/a>\n\t\t\t\t
\n\t\t\t\t

\n\t\t\t\n\t\t\t\tHSG Announces Completion of Global Acquisition of Moxifloxacin Business\t\t\t<\/a>\n\t\t<\/h3>\n\t\t\t\t
\n\t\t\t

(Singapore\/Shanghai | February 2, 2026) Sequoia China announced that on February 2, 2026, it officially completed the global acquisition of the business and assets related to moxifloxacin (brand name: Baifulu\u00ae\/ Avelox\u00ae), and has established Hangzhou Shanze Biopharmaceutical Co., Ltd. (hereinafter \u201cShanze Biopharm\u201d), an innovative biopharmaceutical company focused on anti-infectives, respiratory, and critical care, with its parent company, Ascenda Pte. Ltd., responsible for the operations of this business. Pursuant to the agreement, Shanze Bio and its parent company, Ascenda Pte. Lt<\/p>\n\t\t<\/div>\n\t\t\t\t\t

\n\t\t\n\t\t\n\t\t\tSee More >\t\t<\/a>\n\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/article>\n\t\t\t\t<\/div>\n\t\t\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\tSee More<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"

\u805a\u7126\u6025\u91cd\u75c7\u3001\u6297\u611f\u67d3\u548c\u547c\u5438\u9886\u57df\u7684\u751f\u7269\u533b\u836f\u9886\u519b\u8005 \u6211\u4eec\u7684\u4f7f\u547d \u4ee5\u521b\u65b0\u548c\u901f\u5ea6\u5b88\u62a4\u4eba\u7c7b\u5065\u5eb7 \u6211\u4eec\u7684\u4ef7\u503c\u89c2 \u8bda\u4fe1 \u654f\u6377 […]<\/p>","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-519","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/2606175gud45.adwebcloud.com\/en\/wp-json\/wp\/v2\/pages\/519","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/2606175gud45.adwebcloud.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/2606175gud45.adwebcloud.com\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/2606175gud45.adwebcloud.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/2606175gud45.adwebcloud.com\/en\/wp-json\/wp\/v2\/comments?post=519"}],"version-history":[{"count":0,"href":"https:\/\/2606175gud45.adwebcloud.com\/en\/wp-json\/wp\/v2\/pages\/519\/revisions"}],"wp:attachment":[{"href":"https:\/\/2606175gud45.adwebcloud.com\/en\/wp-json\/wp\/v2\/media?parent=519"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}